FEATURED COMPANIES
- Biogen Inc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Novartis AG
- Pfizer Inc
Central Nervous System Drugs Global Market Report 2020-30: COVID-19 Implications and Growth from the publisher covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for central nervous system drugs which play a critical role in the treatment of patients with COVID-19.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the central nervous system drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Central Nervous System Drugs Market global report from the publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider central nervous system drugs market, and compares it with other markets.
Scope
Markets Covered:
1) By Type: Analgesics; Anti-Parkinson drugs; Anesthetics; Anti-Epileptics; Other CNS drugs
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Companies Mentioned: Biogen Inc; F. Hoffmann-La Roche Ltd; Johnson & Johnson; Pfizer Inc; Novartis AG
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, central nervous system drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the central nervous system drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Central Nervous System Drugs Market global report from the publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider central nervous system drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The central nervous system drugs market section of the report gives context. It compares the central nervous system drugs market with other segments of the central nervous system drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, central nervous system drugs indicators comparison.
Scope
Markets Covered:
1) By Type: Analgesics; Anti-Parkinson drugs; Anesthetics; Anti-Epileptics; Other CNS drugs
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Companies Mentioned: Biogen Inc; F. Hoffmann-La Roche Ltd; Johnson & Johnson; Pfizer Inc; Novartis AG
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, central nervous system drugs indicators comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Biogen Inc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Novartis AG
- Pfizer Inc
1. Executive Summary2. Report Structure7. Central Nervous System Drugs Market Trends And Strategies20. Key Mergers And Acquisitions In The Central Nervous System Drugs Market24. Copyright And Disclaimer
3. Central Nervous System Drugs Market Characteristics
4. Central Nervous System Drugs Market Product Analysis
5. Central Nervous System Drugs Market Supply Chain
6. Central Nervous System Drugs Market Customer Information
8. Central Nervous System Drugs Market Size And Growth
9. Central Nervous System Drugs Market Regional Analysis
10. Central Nervous System Drugs Market Segmentation
11. Central Nervous System Drugs Market Metrics
12. Asia-Pacific Central Nervous System Drugs Market
13. Western Europe Central Nervous System Drugs Market
14. Eastern Europe Central Nervous System Drugs Market
15. North America Central Nervous System Drugs Market
16. South America Central Nervous System Drugs Market
17. Middle East Central Nervous System Drugs Market
18. Africa Central Nervous System Drugs Market
19. Central Nervous System Drugs Market Competitive Landscape
21. Market Background: Pharmaceutical Drugs Market
22. Recommendations
23. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Biogen Inc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Novartis AG
- Pfizer Inc
North America was the largest region in the global central nervous system drugs market, accounting for 48% of the market in 2019. Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market. Africa was the smallest region in the global central nervous system drugs market.
Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drug maker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drug maker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
The central nervous system drugs market consists sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that produce central nervous system drugs to treat brain and spinal cord diseases. This industry includes establishments that produce nervous system drugs, pain reducing analgesics, anti-Parkinson drugs to treat Parkinson’s disease, anticonvulsant anti-epileptics drugs to control epileptic seizures, anesthetics and other drugs such as muscle relaxants, antiemetics..
The global central nervous system drugs market is expected to grow from $123.4 billion in 2019 to $136.7 billion in 2020 at a compound annual growth rate (CAGR) of 10.8%. This growth is mainly due to the COVID-19 outbreak and the neuroinvasive nature of the virus. The CNS is more prone to the viral infection. The virus affects the senses of smell and taste and therefore it is important to curb the interaction between the viral protein and the human receptor, and this factor is driving the demand for CNS drugs. The market is then expected to recover and grow at a CAGR of 6% from 2021 and reach $160.4 billion in 2023.
Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2017, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drug maker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drug maker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
The central nervous system drugs market consists sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that produce central nervous system drugs to treat brain and spinal cord diseases. This industry includes establishments that produce nervous system drugs, pain reducing analgesics, anti-Parkinson drugs to treat Parkinson’s disease, anticonvulsant anti-epileptics drugs to control epileptic seizures, anesthetics and other drugs such as muscle relaxants, antiemetics..
The global central nervous system drugs market is expected to grow from $123.4 billion in 2019 to $136.7 billion in 2020 at a compound annual growth rate (CAGR) of 10.8%. This growth is mainly due to the COVID-19 outbreak and the neuroinvasive nature of the virus. The CNS is more prone to the viral infection. The virus affects the senses of smell and taste and therefore it is important to curb the interaction between the viral protein and the human receptor, and this factor is driving the demand for CNS drugs. The market is then expected to recover and grow at a CAGR of 6% from 2021 and reach $160.4 billion in 2023.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Biogen Inc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Pfizer Inc
- Novartis AG
Note: Product cover images may vary from those shown
LOADING...